{"id":2367,"date":"2026-03-09T05:14:19","date_gmt":"2026-03-09T05:14:19","guid":{"rendered":"https:\/\/www.colapapers.com\/?p=2367"},"modified":"2026-03-09T05:14:21","modified_gmt":"2026-03-09T05:14:21","slug":"week-2-pharmacology-prescriptions-and-managing-lipids","status":"publish","type":"post","link":"https:\/\/www.essaybishops.com\/dissertations\/week-2-pharmacology-prescriptions-and-managing-lipids\/","title":{"rendered":"Week 2 pharmacology prescriptions and managing lipids"},"content":{"rendered":"

Week 2 Advanced Pharmacology Prescription-Safety Assignment for Stable Angina, CYP450 Metabolism, and Hyperlipidemia Management in Primary Care and NP Practice<\/h1>\n

Safe prescribing in advanced pharmacology starts with writing complete, legible, and guideline\u2011concordant orders that specify drug, dose, route, frequency, quantity, refills, and patient\u2011centered instructions aligned with ACC\/AHA, ADA, and GINA recommendations for cardiovascular and metabolic risk reduction. In a strong submission, you would correct each problematic order in Scenario 1, identify the drug class and mechanism of action, and briefly justify changes using current evidence, such as PCSK9 inhibitors for high\u2011risk hyperlipidemia when statins are insufficient or not tolerated (Grundy et al., 2019). You would then explain in Scenario 2 why first\u2011pass hepatic metabolism renders oral nitroglycerin clinically ineffective, describe routes that bypass first pass, and provide a complete nitroglycerin prescription with patient teaching on timing and safety. In Scenario 3, you would identify the pill using Drugs.com, determine its CYP450 metabolic pathway, and discuss how inhibitors or inducers may require dose adjustments or alternative therapies to prevent adverse events. Scenario 4 would integrate ASCVD risk factors, BMI assessment, smoking status, and lipid values to build a goals\u2011based treatment plan using statins, non\u2011statin agents when indicated, and lifestyle counseling that reflects contemporary cholesterol guidelines for primary prevention. A concise, clinically reasoned answer that combines clear prescriptions, mechanism\u2011based explanations, and up\u2011to\u2011date guideline citations will typically perform well academically and serve as a useful study resource for other students searching online for similar advanced pharmacology case solutions.<\/p>\n

Directions and assignment expectations<\/h2>\n

Directions: For each of the scenarios below, answer the questions using your required learning resources, Medscape, and clinical practice guidelines (ie AHA, ACC, ADA, GINA). To support sound clinical decision making and current best practice, you are encouraged to integrate at least one recent guideline or evidence summary from reputable organizations such as the American Heart Association (AHA), American College of Cardiology (ACC), and the American Diabetes Association (ADA) when formulating your responses.
\nWhen recommending medications, write out a complete prescription for each medication. You should think about how your prescriptions would appear if they were sent electronically or phoned in, including all legally required components and any safety\u2011focused comments that would help the pharmacist counsel the patient. What order would you send to a pharmacy? Include drug, dose, route, frequency, # dispensed (days supply), refills, special instructions etc. Also state if you would continue, discontinue or taper the patient\u2019s current medications (if applicable). Use at least 3 sources for each scenario and cite sources using APA format. LIST REFERENCES AFTER EACH SCENARIO.<\/p>\n

Assignment attempts and submission policy<\/h2>\n

Note on Assignment Attempts
\nStudents are expected to review their work and submissions of work carefully prior to due dates. Careful proofreading, checking APA citations, and confirming that each scenario includes complete prescriptions and appropriate guideline references will help you make the most of your single graded attempt.
\nUnless otherwise approved by the faculty, students are allowed one submission of graded work per assignment. While the classroom allows for multiple submissions, once an assignment is graded, submissions will no longer be accepted unless approved by the faculty. If an assignment is submitted prior to the assignment deadline and has not yet been graded, then students may submit a revised assignment prior to the assignment deadline. In planning your work, allow enough time to incorporate faculty announcements or clarifications posted earlier in the week before you submit your final version. Once the deadline has passed, resubmission is not permitted.<\/p>\n

Late assignment policy<\/h2>\n

Late Assignment Policy
\nStudents are expected to submit assignments by the due dates noted in the course and welcome announcement. In extenuating circumstances, such as illness, the student must contact the instructor as soon as possible to discuss the situation. In those circumstances, faculty will determine the appropriate course of action for the student. Depending on the situation, these actions may include recommendations to drop the course (if within the university drop\/withdrawal period), acceptance of some or all of the overdue assignments with or without penalties, or failure to accept assignments. Assignments submitted late without the prior agreement of the instructor, outside of an emergency absence, or in violation of agreements for late submission, will receive a grade reduction for the assignment amounting up to 20%. Each day late will result in a 4% point deduction up to day 5. After 5 days, the assignment will be graded a zero. However ALL assignments, quizzes, and exams must be completed to pass the course.<\/p>\n

Wishing you much success,
\nDr. Ridley<\/p>\n

Week 2 assignment overview<\/h2>\n

WEEK 2 ASSIGNMENT (covers weeks 1-2)
\nThis multi\u2011scenario assignment is designed to strengthen your clinical reasoning around cardiovascular pharmacology, adverse event prevention, and safe prescribing, while also reinforcing your familiarity with primary sources such as clinical guidelines, Medscape monographs, and Drugs.com tools.
\nSCENARIO 1<\/p>\n

Scenario 1: Prescription errors, classification, and MOA<\/h3>\n

What are the errors in the following prescriptions (1 per prescription)? Rewrite each prescription correctly. What is each medication\u2019s classification and mechanism of action (MOA)? Clarifying these issues will help you practice how to spot unsafe or incomplete orders and how to align each medication with its therapeutic role in conditions like hyperlipidemia and heart failure.
\n\u00b7 Repatha 140 mg IV every 2 weeks #1 1 RF
\n\u00b7 Hyzaar (losartan\/hydrochlorothiazide) 50\/25 mg PO daily #30 3 RF
\n\u00b7 digoxin 1.25 mg PO daily #30 1 RF
\n\u00b7 hydralazine\/isosorbide mononitrate (BiDil) 37.5 mg\/20 mg PO every 8 hours #90 1 RF
\n\u00b7 clonidine 0.3 mg patch PO once weekly #4 1 RF<\/p>\n

Scenario 2: Nitroglycerin, first\u2011pass metabolism, and routes<\/h3>\n

SCENARIO 2
\nA patient with stable angina is prescribed nitroglycerin. The provider avoids oral tablets and instead chooses a sublingual or transdermal formulation. Why is oral nitroglycerin not clinically useful? Discuss how first-pass metabolism affects nitroglycerin\u2019s bioavailability and define both terms. Identify the route of administration with 100% bioavailability and explain how alternative routes overcome the first pass effect. Include a sample prescription for nitroglycerin. In your response, aim to connect pharmacokinetic concepts such as bioavailability and hepatic metabolism to practical prescribing choices that improve symptom relief and reduce risk in patients with ischemic heart disease.<\/p>\n

Scenario 3: CYP450 location, pill identification, and MTM<\/h3>\n

SCENARIO 3
\nWhere are the majority of cytochrome P450 (CYP) enzymes located? Using the Drugs.com pill identifier, enter the following characteristics to identify the medication AND strength. What CYP enzyme metabolizes this medication? How can this information be applied to medication therapy management? Write a sample prescription for the identified medication and strength. You should also discuss how knowledge of CYP pathways can guide you in avoiding harmful drug\u2013drug interactions and in tailoring doses in patients who take multiple chronic medications.<\/p>\n

Scenario 4: Lipid management, BMI, and CAD risk<\/h3>\n

SCENARIO 4
\nKU is a 47-year-old male following up on his labs that were drawn last week. He smokes 1 pack per day. He is currently on lisinopril 40 mg po daily, liraglutide (Victoza) 0.6 mg subcutaneously once daily and St. John\u2019s Wort. Fasting lipid profile shows total cholesterol 260 mg\/dL, LDL 180 mg\/dL, HDL 43 mg\/dL, and TG 185 mg\/dL. He is 5\u20199\u201d and weighs 204 lbs. What treatment plan would you implement for KU? What are GOAL Total Cholesterol (TC), HDL, LDL, and Triglyceride levels for KU? What is his BMI per Medscape calculator? What patient monitoring and education would you provide? How many risk factors for coronary artery disease does this patient have? Identify them specifically. As you answer, draw directly on recent cholesterol guidelines to justify your target lipid levels and therapy choices, and make sure your education plan addresses smoking cessation, weight management, and potential interactions such as St. John\u2019s Wort with other cardiovascular drugs.<\/p>\n

Grading rubric and performance criteria<\/h2>\n

The criteria below guide how your work will be evaluated in terms of clinical accuracy, use of evidence, and clarity of written communication.<\/p>\n

Scenario 1 criteria<\/h3>\n